(Q51749083)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

chronic lymphocytic leukemia

10 March 2020

main subject

lymphocyte

0 references

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Marta Crespo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Carlos Palacio

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Francesc Bosch

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

N Purroy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

P Abrisqueta

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

J Carabia

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

C Carpio

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

E Calpe

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

12 March 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

1993-2004

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells

10 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

The triterpenoid CDDO induces apoptosis in refractory CLL B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Chronic lymphocytic leukemia B cells are endowed with the capacity to attract CD4+, CD40L+ T cells by producing CCL22

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

In vitro sensitivity of CLL cells to fludarabine may be modulated by the stimulation of Toll-like receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

The case for survivin as a regulator of microtubule dynamics and cell-death decisions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

HBXIP functions as a cofactor of survivin in apoptosis suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Molecular circuits of apoptosis regulation and cell division control: the survivin paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Expression and prognostic significance of the inhibitor of apoptosis protein (IAP) family and its antagonists in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Mcl-1 downregulation by YM155 contributes to its synergistic anti-tumor activities with ABT-263.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Targeting survivin and p53 in pediatric acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Combination of YM155, a survivin suppressant with a STAT3 inhibitor: a new strategy to treat diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Sepantronium bromide (YM155) enhances response of human B-cell non-Hodgkin lymphoma to rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

A phase II study of the survivin suppressant YM155 in patients with refractory diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Drug combination studies and their synergy quantification using the Chou-Talalay method

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

The "survivin suppressants" NSC 80467 and YM155 induce a DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Histone H2A phosphorylation in DNA double-strand break repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Regulation of DNA double-strand break repair pathway choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Role of the microenvironment in chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Survivin is required for stable checkpoint activation in taxol-treated HeLa cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

A role for survivin in chemoresistance of endothelial cells mediated by VEGF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Suppression of colorectal tumor growth by regulated survivin targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Transcriptional analysis of human survivin gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

The functional in vitro response to CD40 ligation reflects a different clinical outcome in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2014.96

B-cell chronic lymphocytic leukemia: a bird of a different feather

21 January 2018

1 reference

12 December 2020

Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells

1 reference

12 December 2020

Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1.

1 reference

12 December 2020

Synergistic effect of survivin-specific small interfering RNA and topotecan in renal cancer cells: topotecan enhances liposome-mediated transfection by increasing cellular uptake.

1 reference

12 December 2020

Chronic lymphocytic leukemia--an accumulative disease of immunolgically incompetent lymphocytes.

1 reference

12 December 2020

Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines

1 reference

12 December 2020

Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial

1 reference

12 December 2020

Apoptotic and proliferative characteristics of proliferation centers in lymph node sections of patients with chronic lymphocytic leukemia.

1 reference

12 December 2020

Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1.

1 reference

12 December 2020

Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells

1 reference

12 December 2020

CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens

1 reference

12 December 2020

Therapeutic potential of sepantronium bromide YM155 in gemcitabine-resistant human urothelial carcinoma cells

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2014.96

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24618734%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference